Ghada Salum

Dr. Ghada Salum


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
RDReham M. Dawood
Reham M. Dawood
MEMai A. El-Meguid
Mai A. El-Meguid
GSGhada Salum
Ghada Salum
MAMostafa K. El Awady
Mostafa K. El Awady
Hepatic fibrosis is a complex mechanism defined by the net deposition of the extracellular matrix (ECM) owing to liver injury caused by multiple etiologies such as viral hepatitis and nonalcoholic fatty liver disease. Many cell types are implicated in liver fibrosis development and progression. In general, liver fibrosis starts with the recruitment of inflammatory immune cells to generate cytokines, growth factors, and other activator molecules. Such chemical mediators drive the hepatic stellate cells (HSCs) to activate the production of the ECM component. The activation of HSC is thus a crucial event in the fibrosis initiation, and a significant contributor to collagen deposition (specifically type I). This review explores the causes and mechanisms of hepatic fibrosis and focuses on the roles of key molecules involved in liver fibro genesis, some of which are potential targets for therapeutics to hamper liver fibro genesis.

12 September 2019 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
NDNoha G. Bader El Din
Noha G. Bader El Din
MIMarwa K. Ibrahim
Marwa K. Ibrahim
REReem El‐Shenawy
Reem El‐Shenawy
GSGhada Salum
Ghada Salum
SFSally Farouk
Sally Farouk
MAMostafa El Awady
Mostafa El Awady

1 September 2020 in Genes & Diseases
Verified
Journal Article
Open access
GSGhada Salum
Ghada Salum
RDReham Dawood
Reham Dawood
MEMai Abd El-Meguid
Mai Abd El-Meguid
NINoha E. Ibrahim
Noha E. Ibrahim
AAAshraf O. Abdel Aziz
Ashraf O. Abdel Aziz
MAMostafa K. El Awady
Mostafa K. El Awady
In Egypt, Sofosbuvir (SOF) in combination with Dataclasvir (DCV) is the broadly used DAAs with excellent therapeutic profile. This study is designed to explore the relation between IL28B/TLR4 genetic variants and each of the followings; HCC development post SOF/DCV treatment, progression to HCC in naïve patients and SOF/DCV therapy outcome. A total of 493 blood samples were collected (controls (n = 70); HCV patients treated with SOF/DCV (n = 252) of whom 65 patients developed HCC, 187 patients didn't develop HCC (125 responders, 62 relapsers); naïve HCV patients (n = 171) had early (n = 48), late liver fibrosis (n = 21) and HCC (n = 102)). Both SNPs were genotyped using a TaqMan 5′ allelic discrimination assay. At IL28B rs12979860 SNP, the C allele was significantly correlating with the response rate more than T allele (OR 1.9, 95% CI 1.29–2.9, p = 0.004), while at TLR4 rs4986791 SNP, no association was found (OR 6.5, 95% 0.57–75.28, p = 0.09). Both SNPs couldn't detect the probability for HCC emergence after treatment. In naïve patients, the protective alleles were detected in their lowest frequency in HCC patients (p = 0.1, for rs12979860 and, p = 0.001 for rs4986791). SOF/DCV combination improved SVR rates in HCV genotype 4a infected patients regardless of IL28B genotype, with the best rates in those lacking the T allele.

1 July 2017 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
GSGhada Salum
Ghada Salum
NDNoha G. Bader El Din
Noha G. Bader El Din
MIMarwa K. Ibrahim
Marwa K. Ibrahim
MAMohamed Mohamed Anany
Mohamed Mohamed Anany
RDReham Dawood
Reham Dawood
MAMostafa El Awady
Mostafa El Awady
The major complication of hepatitis C virus (HCV) infection is the induction of hepatic fibrosis. In this study, we investigated the correlation between the expression level of vascular endothelial growth factor (VEGFA) at mRNA and protein levels and the progression of HCV-related liver fibrosis. One hundred twenty subjects were selected for this study: 15 controls and 105 chronic HCV patients with different fibrosis grades (44 F0–F1 and 61 F2–F4). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure VEGFA mRNA in peripheral blood mononuclear cells, while enzyme-linked immunosorbent assay (ELISA) was used to measure the secreted VEGFA protein in serum. Both qRT-PCR and ELISA results showed that HCV patients have significantly higher VEGFA expression than that of controls (P = 0.036 and 0.043, respectively). Moreover, patients with late fibrotic stages (F2-F4) exhibited the highest levels of VEGFA mRNA and protein (P = 0.008 and 0.041, respectively) when compared with controls. An area under the receiver operating characteristic curve (AUC of the ROC) for the circulatory VEGFA protein between HCV patients with fibrosis and healthy controls was 0.92 (P = 0.043). Our data suggest that VEGFA protein is a promising noninvasively diagnostic biomarker for HCV-induced liver fibrosis.

2 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MIMarwa K. Ibrahim
Marwa K. Ibrahim
GSGhada Salum
Ghada Salum
NDNoha G. Bader El Din
Noha G. Bader El Din
RDReham Dawood
Reham Dawood
ABAhmed Barakat
Ahmed Barakat
MAMostafa El Awady
Mostafa El Awady
IFN orchestrates the expression of various genes to halt hepatitis C virus (HCV) replication with the possibility of either reduced or increased liver fibrosis; due to controlled viral replication or overproduction of inflammatory mediators, repectively. In this study, we examined the transcriptional profiling of type I IFN related genes in HCV-chronically infected patients with varying degrees of liver fibrosis. PCR array was used to examine the expression of 84 type I IFN related genes in peripheral blood mononuclear cells (PBMCs) RNA from 12 treatment-naïve chronic HCV patients (5 F0-F1 and 7 F2-F4) and 5 healthy subjects. We further validated our results by quantitative real time PCR (qRT-PCR) in 103 treatment-naïve chronic HCV patients (43 F0-F1 and 60 F2-F4) and 15 controls. PCR array data revealed dysregulation in TLR7 pathway. The expression of TLR7 was decreased by 4 folds and MyD88 was increased by 3 folds in PBMCs of F2-F4 patients when compared to the healthy volunteers (p = 0.03 and 0.002, respectively). In addition, IRF7 and TLR7 showed dramatic downregulation (6 and 8 folds, respectively) in F2-F4 patients when compared to F0-F1 ones. qRT-PCR confirmed the altered expression patterns of TLR7 and MyD88 in F2-F4 patients when compared to either controls or F0-F1 patients. However, by qRT-PCR, IRF7 and NF-κB1 (TLR7 pathway transcription factors) exhibited similar mRNA abundance among F2-F4 and F0-F1 patients. These results suggest that TLR7 and MyD88 are possible candidates as biomarkers for the progression of HCV-induced liver fibrosis and/ or targets for therapeutic intervention.

1 September 2020 in Gene
Verified
Journal Article
Closed access
RDReham Dawood
Reham Dawood
GSGhada Salum
Ghada Salum
MEMai Abd El-Meguid
Mai Abd El-Meguid
MSMohamed Shemis
Mohamed Shemis
AAAshraf O. Abdel Aziz
Ashraf O. Abdel Aziz
MAMostafa K. El Awady
Mostafa K. El Awady